In addition, our IHC results implied that Ki-67, which is widely used as a cell proliferation marker [21], was markedly down-regulated by treatment of PK5-RL-Gal-3C compared to negative control (Fig. 2G and H), which also confirmed the inhibitory activity of our novel fusion protein on tumor growth in vivo. Here, GAL is linked to neoplasm.